Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 11Meningioma 5Prostatic Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neuroblastoma 2Medulloblastoma 2Glioma 2Glioblastoma 2Carcinoma, Merkel Cell 2Sarcoma, Synovial 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma 1Carcinoid Tumor 1Advanced Lung Neuroendocrine Tumor 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1Adenoma, Islet Cell 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1lanreotide 1fluorodopa F 18 1cabozantinib 1Sunitinib 1Random Allocation 1Octreotide 1Nivolumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × lutetium Lu 177 dotatate × 90 days × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡